阿戈美拉汀与SSRI、SNRI类药物治疗抑郁症疗效与安全性的Meta分析

发布时间：2018-02-14 15:49

本文关键词： 阿戈美拉汀抑郁症 Meta分析随机对照试验　出处：《重庆医科大学学报》2017年10期 　论文类型：期刊论文

【摘要】：目的:利用Meta分析的方法分别评估阿戈美拉汀与选择性5-羟色胺再摄取抑制剂(selective serotonin reuptake inhibitor,SSRI)、选择性5-羟色胺和去甲肾上腺素再摄取抑制剂(serotonin noradrenaline reuptake inhibitor,SNRI)类药物治疗抑郁症的疗效,为临床治疗提供参考。方法:计算机检索Cochrane library、Pubmed、Elsevier、中国知网、维普数据库、中国生物医学数据库、万方数据库,收集阿戈美拉汀与SSRI、SNRI类药物治疗抑郁症的随机对照试验(randomized controlled trial,RCT),对符合纳入标准的临床研究进行质量评价和资料提取后,采用Rev Man5.2统计软件进行Meta分析。结果:研究共纳入8项RCTs,总计2 632例患者;Meta分析结果显示,阿戈美拉汀组患者有效率(RR=1.07,95%CI=1.01~1.12,P=0.010)、治愈率(RR=1.10,95%CI=1.01~1.20,P=0.030)均明显高于SSRI、SNRI类药物组,抑郁量表终点评分与基线的差值值高于SSRI、SNRI类药物组(MD=0.46,95%CI=-0.13,1.05,P=0.130),2组差异无统计学意义。阿戈美拉汀在不良反应反应方面优于SSRI、SNRI类药物组(RR=0.50,95%CI=0.37~0.68,P=0.000),差异存在统计学意义。结论:阿戈美拉汀较其他SSRI、SNRI类药物治疗抑郁症的疗效更好、更安全。尚需高质量、大样本RCT研究进一步验证。
[Abstract]:Objective: to evaluate the efficacy of agomelatin, selective serotonin reuptake inhibitor, selective serotonin and norepinephrine reuptake inhibitor, serotonin noradrenaline reuptake inhibitor SNRI, in the treatment of depression. Methods: to search Cochrane librarylary pubmedmedus Elsevier, China knowledge Network, Weip Database, Chinese Biomedical Database, Wanfang Database, and to provide reference for clinical treatment. A randomized controlled trial of Agonelatin and SSRI SNRI in the treatment of depression was conducted, and the quality evaluation and data extraction of the clinical studies that met the inclusion criteria were carried out. Results: a total of 2 632 patients were included in the study. The results of meta-analysis showed that the effective rate of patients in the Agonolatine group was 1.01 ~ 1.12 ~ 1. 12% P0. 010 ~ 0, and the cure rate was significantly higher than that in the SSRI SNRI group, and the cure rate was significantly higher than that in the SSRI SNRI group, and the cure rate was higher than that in the SSRI SNRI group, and the cure rate was significantly higher than that in the SSRI SNRI group, and the cure rate was significantly higher than that in the SSRI SNRI group, and the cure rate was significantly higher than that in the SSRI SNRI group. The difference between the end point score and baseline score of depression scale was higher than that in SSRI SSRI SNRI group. There was no significant difference between the two groups. Agomelatin was better than SSRI SNRI group in adverse reactions, RR0.5095CI0.370.68P0.0000.Conclusion: there is a significant difference between two groups. Melatine is more effective in the treatment of depression than other SSRI- SNRI drugs. Safer. High quality, large sample RCT research is needed for further validation.
【作者单位】：南昌大学第一附属医院心身医学科;南昌大学第一附属医院康复医学科;
【分类号】：R749.4

【相似文献】